Co-Investment

,

Deal Announcement: Alto Pharmacy

,

CHRYSTAL CAPITAL INTRODUCES CO-INVESTORS TO SECONDARY CAPITAL  

 

Chrystal Capital Partners LLP (“Chrystal”), a Mayfair-based corporate finance and investment house, is pleased to announce that it has acted as introducer of capital to Secondary Capital on its acquisition of secondary shares in Alto Pharmacy (“Alto”), a US leading digital pharmacy.   

“Secondary share purchases in well-established, profitable and well-funded tech businesses; through founder led processes, is an area that we had been trying to gain access to for some time. Having now completed our first transaction with Secondary Capital in Alto Pharmacy we look forward to working with them with regards to their investments in other US and European based opportunities.”
— James Innes, Managing Partner, Chrystal Capital
“Chrystal Capital introduced us to a significant number of family offices and private individuals based in both the UK and Europe. They worked alongside us to present the investment case in Alto Pharmacy and it was clear that they have the trust of their network.”
— Cedric Abitbol, Secondary Capital

About Alto Pharmacy (“Alto”) 

  

Alto is America's leading digital pharmacy with free hand-delivery, easy-to-reach pharmacists, and automatic savings investigations. Founded in 2015, Alto’s better pharmacy model is centered on the critical role of pharmacists as the final link in a person’s health journey and combines expert pharmacist care with purpose-built technology to deliver a more convenient and affordable experience for those who need medication. To date, Alto has fulfilled more than three million prescriptions, expanded to twelve markets, and built a mobile app experience that makes it easier than ever to manage medications and chat with a pharmacist.  

 

For more information about Alto Pharmacy, please visit https://alto.com/. 

 

About Chrystal Capital Co-investments 

 

Single Family Offices (SFOs) and Ultra High Net Worth Individuals (UHNWIs) are continually seeking access to high quality, professionally structured and well managed co-investment opportunities across a range of asset classes, without having to directly source and negotiate these opportunities. The ideal scenario enables our clients to cherry pick the investment opportunities they participate in, with limited demands on their time and resources. 

 

Through our relationships with institutional investors, we enable SFOs and UHNWIs to gain access to attractive investment opportunities that they might otherwise not be aware of. We provide curated deal flow across a variety of sectors, asset classes and structures – all tailored to known, specified preferences. 

 

For more information about Chrystal Capital please visit https://www.chrystalcapital.com. 

 

About Secondary Capital (“SC”) 

 

SC was established by veteran Private Markets Investors, active in both primary and secondary transactions since the early 2000's. 

  

SC is aligned to a fundamental shift that companies are staying private longer and need transitional capital to provide liquidity to early investors, founders and executives.  SC, as a direct secondary specialist, provides liquidity to shareholders (founders, executives, VC funds and other early investors) of late-stage and growth companies. 

 

For more information about Secondary Capital please visit https://www.secondary-capital.com. 

 

 
For further information please contact:  
James Innes, Managing Partner 
james.innes@chrystalcapital.com  
https://www.chrystalcapital.com  

Deal Announcement: Seneca Property

CHRYSTAL CAPITAL INTRODUCES FAMILY OFFICES AND UHNWI CO-INVESTORS TO SENECA PROPERTY

Chrystal Capital Partners LLP (“Chrystal”), a Mayfair-based corporate finance and investment house, is pleased to announce that it has acted as an introducer of capital to Seneca Property Investments Limited (“Seneca Property), an independent real estate investor, on its £7m purchase of the Premier Inn, Preston.  

“We work closely with several family offices to develop new investment theses and there is demand for the protection and income that real assets provide. We therefore went into the market and spent time speaking with property asset managers and decided to work with Seneca as their approach of buying quality assets at discounted prices from motivated sellers resonated with both us and our network.”
— James Innes, Managing Partner, Chrystal Capital
“

There is no doubt that Chrystal Capital have demonstrated the broad network of investors that trust their judgement on picking investment partners. The process has been both professional in nature and been completed in a timely manner.
”
— Chris Bullough, Managing Director, Seneca Property

About Seneca Property

 

Seneca Property is an independent real estate investor which seeks to provide exceptional income and growth investment opportunities for investors. Seneca invest across a range of sectors including office, retail, leisure, industrial, residential and healthcare.

 

For more information about Seneca Property, please visit https://senecaproperty.com/.

 

About Chrystal Capital Co-investments

 

Single Family Offices (SFOs) and Ultra High Net Worth Individuals (UHNWIs) are continually seeking access to high quality, professionally structured and well managed co-investment opportunities across a range of asset classes, without having to directly source and negotiate these opportunities. The ideal scenario enables our clients to cherry pick the investment opportunities they participate in, with limited demands on their time and resources.

 

Through our relationships with institutional investors, we enable SFOs and UHNWIs to gain access to attractive investment opportunities that they might otherwise not be aware of. We provide curated deal flow across a variety of sectors, asset classes and structures – all tailored to known, specified preferences.

 

For more information about Chrystal Capital please visit https://www.chrystalcapital.com.


For further information please contact: 
James Innes, Managing Partner
james.innes@chrystalcapital.com 
https://www.chrystalcapital.com 

,

Deal Announcement: Cera Care

,

CHRYSTAL CAPITAL INTRODUCES FAMILY OFFICES AND UHNWI CO-INVESTORS INTO CERA CARE ALONGSIDE GUINNESS VENTURES

Chrystal Capital Partners LLP (“Chrystal”), a Mayfair-based corporate finance and investment house, is pleased to announce that it has brought co-investors from its family office and UHNWI network into Cera Care (“Cera”); a digital-first healthcare-at-home service delivering care, nursing, telehealth and repeat prescription services in people’s homes, via technology.

The funds, invested via a UK nominee structure, will be managed by Guinness Ventures (“Guinness”), an existing investor in Cera Care having invested via the Guinness EIS fund. Other notable investors in this round include; Credo Ventures, Kairos, Jane Street Capital and Schroders Capital.

“We believe that there is significant value to be had for our network to invest in businesses of scale, alongside institutional capital. There is a gap in the market where existing investors, for a variety of reasons, cannot participate in follow-on rounds. We have a focused list of current opportunities and would welcome conversations with those that find the idea of a low cost entry point, into top tier opportunities, alongside ‘Blue Chip’ operators, appealing.”
— James Innes, Managing Partner, Chrystal
“We are pleased to announce that we have now closed this round of financing. Thanks to the help of Chrystal we can continue to support Cera Care in bringing their vision of in-home care to life. Chrystal were instrumental in taking much of the strain of the marketing and deal transaction processes.”
— Shane Gallwey, Head of Ventures, Guinness Ventures

About Cera

Cera, founded in 2015, provides elderly and vulnerable communities with care in their own homes, and allows families to arrange the care. As one of Europe’s fastest-growing companies, they are redefining healthcare by moving more and more services out of hospitals and into people’s own homes. Their smart, digital technology leverages data and machine learning to empower those providing care, whilst improving outcomes for those receiving it.

For those delivering care, Cera reduces the burden of ‘pen and paper’ working and remove unnecessary administrative work, empowering them to do what they do best: care.

For those receiving care at home Cera are able to monitor their condition digitally, predicting and preventing changes in their condition and responding to any deterioration 30-fold faster than traditional methods, reducing hospitalisations, and keeping people well in their homes.

For more information, see https://ceracare.co.uk/

About Guinness

Guinness has invested into growth businesses since 2010, providing capital to a wide range of UK companies backing outstanding entrepreneurs and businesses with disruptive and ambitious growth plans. They have successfully supported the growth of over 100 companies since 2010 and are always excited to meet passionate entrepreneurs.

For more information, see https://www.guinnessgi.com/

About Chrystal

Chrystal is an entrepreneurial corporate finance and investment house with an established global network of Single Family Offices, Ultra High Net Worth Individuals and private equity co-investment partners. We act as a conduit between our network members, providing bespoke solutions for their capital and investment objectives.

Our core sectors are Digital Economy, Health & Wellness, Sustainable & Impact Investments, and Natural Resources.

Our service areas are Advisory, Principal Investments and Co-investments.

For further information please contact:

James Innes
Managing Partner
james.innes@chrystalcapital.com
https://www.chrystalcapital.com

,

Deal Announcement: Remilk

,

CHRYSTAL CAPITAL INTRODUCES FO AND UHNWI CO-INVESTORS INTO A SECONDARY PLACING OF REMILK, ALONGSIDE RAGE CAPITAL


Chrystal Capital Partners LLP (“Chrystal”), a Mayfair-based corporate finance and investment house, is pleased to announce that it has brought members of its family office and UHNWI network into Remilk, a leading precision fermentation company crafting real dairy without a single cow. The investment will be managed by Rage Capital.

“Our co-investment and secondary platform is based on the ability to source and work closely with top tier GPs globally.  This is demonstrated by this latest transaction with Rage Capital who have a demonstrable track record in the alternative proteins space.  I would encourage investors who are open to the idea of having a strong GP alongside them and who want global access to deal flow to come forward to speak to the Chrystal Capital team.”
— James Innes, Managing Partner, Chrystal rce

About Remilk

Remilk is a precision fermentation company that modifies yeast microorganisms to synthesize the proteins found in cow's milk, primarily whey and casein - unlocking the $800B+ dairy market. Precision fermentation is the process of genetically engineering microorganisms (in this case, yeast strains) to stimulate them to produce pure molecules, as has been done in pharma for decades.

Dairy crafted Remilk’s way is a breath of fresh air, with its production process emitting up to 97% less greenhouse gases! It also requires an estimate of around 1% of the land, 4% of the feedstock and less than 10% of the water compared to traditional dairy production - with zero animals harmed.

Remilk has achieved best-in-class yeast titers (or yield) within less than 3 years, a tremendous feat that is further corroborated by customers' positive reviews of the company's proteins.

For more information, see www.remilk.com.

About Chrystal Capital

Chrystal Capital is a corporate finance and investment house with an established global network of Single Family Offices, Ultra High Net Worth Individuals and private equity co-investment partners. We act as a conduit between our network members, providing bespoke solutions for their capital and investment objectives.

For more information, see www.chrystalcapital.com.


About Rage Capital

Rage Capital is a specialist venture capital firm based in New York, investing in cutting edge technology to change the way we eat, live and interact with our planet. Other investments in its portfolio include Blue Nalu, Motif, Ripple, Reef, Future Farm and Splendid Spoon.

For more information, see www.rage-capital.com.

For further information please contact:

James Innes Managing Partner

james.innes@chrystalcapital.com

https://www.chrystalcapital.com

,

Deal Announcement: The Every Company (formally Clara Foods)

,

Chrystal Capital introduces FO and UHNWI co-investors into the $175m Series C financing of The Every Company (formally Clara Foods), alongside Rage Capital



Chrystal Capital Partners LLP (“Chrystal”), a Mayfair-based corporate finance and investment house, is pleased to announce that it has brought co-investors from its family office and UHNWI network into The EVERY Company, a leading precision fermentation platform accelerating a global transition to animal-free protein. The round was co-led by new investor, McWin, and existing investor, Rage Capital. Other new and existing investors joined the round including Temasek, Grosvenor’s Wheatsheaf Group, and TO Ventures.

“Giving family offices access to high growth companies backed by blue chip investors is what Chrystal Capital prides itself on.  Rage Capital is an excellent partner with its vast experience and success in the food tech investing space.  We will be bringing additional deals from them to our network in Q1 and I would encourage any investors interested in the space to reach out.”
— James Innes, Managing Partner, Chrystal

About The Every Company

The EVERY Company, headquartered in South San Francisco, is a market leader in engineering, manufacturing and formulating animal-free, animal proteins as ingredients for the global food and beverage industry. Originally founded as Clara Foods in 2014, EVERY™ rebranded in 2021 to better capture its vision to bring animal-free proteins to everyone, everywhere.  The company use sugar, yeast, and advanced yeast engineering and fermentation technologies to selectively cultivate yeast for the production of proteins, thereby enabling customers to get healthy, sustainable, and affordable protein items.

Founded by Arturo Elizondo in 2014, Clara’s mission is to create a better, cheaper alternative to animal proteins in both B2C and B2B applications – starting with the egg’s $200B addressable market. Today, the company has developed a comprehensive platform from protein discovery to industry-leading yeast productivity, enabling Every to identify both novel proteins or novel applications of known proteins and synthesize those in mass quantities.

For more information, see www.theeverycompany.com.


About Rage Capital

Rage Capital is a specialist venture capital firm based in New York, investing in cutting edge technology to change the way we eat, live and interact with our planet. Other investments in its portfolio include Blue Nalu, Motif, Ripple, Reef, Future Farm and Splendid Spoon.

For more information, see www.rage-capital.com.


For further information please contact:
James Innes
Managing Partner

james.innes@chrystalcapital.com
https://www.chrystalcapital.com

,

Deal Announcement: Candid Co.

,
download.png

Candid Closes $63 Million Series B

Candid, a direct-to-consumer brand expanding access and affordability to oral health care, announced it raised a $63.4M Series B financing round. Participating in the round were Candid’s Seed and Series A investors, including Greycroft, Bessemer, and e.ventures, and featured participation from new investors, including RiverPark Funds, blisce, Redesign Health’s limited partners, and Mousse Partners. This brings Candid’s total funding to nearly $90 million.

The Series B round will fuel Candid’s rapid growth through both its retail and at-home channels, as well as provide capital to double the number of employees to 550 by the end of the year. Candid will be opening an additional 50 Candid Studios across the United States — bringing the total number of retail locations to more than 60 — offering an unparalleled in-person experience to those who seek it while continuing to offer remote treatment for patients in harder-to-access areas of the country. In just 18 months of operation, Candid has already opened 13 studios in major cities across the U.S. and served tens of thousands of customers.

Candid also announced it is donating $25 from every set of aligners it sells to Smile Train , a charity that supports free cleft surgery and comprehensive cleft care for children around the world. This partnership will result in at least 1,000 more cleft surgeries for children in 2019.

For more information or to view Candid’s studio locations visit Candidco.com